|
|
|
|
| LEADER |
01765nam a2200325 u 4500 |
| 001 |
EB002001492 |
| 003 |
EBX01000000000000001164393 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
210907 r ||| eng |
| 245 |
0 |
0 |
|a CADTH Canadian Drug Expert Committee final recommendation: Selexipag (Uptravi -- Actelion Pharmaceuticals Canada Inc.)
|h Elektronische Ressource
|b Indication: pulmonary arterial hypertension
|
| 246 |
3 |
1 |
|a Selexipag (Uptravi -- Actelion Pharmaceuticals Canada Inc.)
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c 2016, October 26, 2016
|
| 300 |
|
|
|a 1 PDF file (6 pages)
|
| 653 |
|
|
|a Canada
|
| 653 |
|
|
|a Cost-Benefit Analysis
|
| 653 |
|
|
|a Acetamides / therapeutic use
|
| 653 |
|
|
|a Hypertension, Pulmonary / drug therapy
|
| 653 |
|
|
|a Pyrazines / therapeutic use
|
| 653 |
|
|
|a Insurance, Health, Reimbursement / economics
|
| 653 |
|
|
|a Antihypertensive Agents / economics
|
| 710 |
2 |
|
|a CADTH Canadian Drug Expert Committee
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH common drug review
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK533883
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 082 |
0 |
|
|a 330
|
| 520 |
|
|
|a The CADTH Canadian Drug Expert Committee (CDEC) recommends that selexipag be reimbursed for long-term treatment of idiopathic pulmonary arterial hypertension (PAH), heritable HPAH, PAH associated with connective tissue disorders, and PAH associated with congenital heart disease, in adult patients with World Health Organization (WHO) functional class (FC) II to III to delay disease progression
|